Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2025)

Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2025)

Docket		Date Filed	2025-05-29
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Parties	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Patents	10,258,637; 11,090,323; 11,833,166; 9,949,998
Attorneys	Megan Elizabeth Dellinger
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-05-29				External link to document

Litigation summary and analysis for: Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2025)

Last updated: July 19, 2026

Boehringer Ingelheim v. Granules India (1:25-cv-00663): Litigation Summary, Claims at Issue, and Risk Outlook

Executive summary: Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Granules India Limited in the U.S. District Court for the Southern District of New York under the Hatch-Waxman framework (case number 1:25-cv-00663). The filing indicates an Orange Book-driven dispute tied to a specific small-molecule product and its FDA marketing/abbreviated-application pathway, with BIPI asserting patent infringement tied to the asserted U.S. patents and Granules’ planned generic launch. The litigation posture is early (new case docket), with key next-cycle risk focused on early claim construction, the asserted-patent list, and any Paragraph IV notices that define the scope of infringement contentions.

What is the Boehringer Ingelheim v. Granules India Limited case 1:25-cv-00663 about?

Short answer: A patent infringement action brought by Boehringer Ingelheim Pharmaceuticals Inc. against Granules India Limited in S.D.N.Y. under the Hatch-Waxman dispute model, centered on a generic entry that BIPI alleges infringes one or more BIPI-owned or controlled Orange Book-listed patents for a specific branded drug.

Forum and caption

• Case: Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited
• Docket: 1:25-cv-00663
• Court: U.S. District Court, Southern District of New York
• Year: 2025 filing

Procedural posture

• The case is newly filed, so the practical drivers are (1) the asserted patent set in the complaint, (2) Granules’ responsive pleadings, and (3) early motion practice (common in Hatch-Waxman) that shapes claim construction and design-around feasibility.

Hatch-Waxman mechanics that typically define the action

• BIPI’s infringement allegations usually track the Paragraph IV framework (or equivalently the ANDA-linked dispute), anchoring the “claims at issue” to the patents listed for the reference product in the Orange Book.
• The lawsuit scope is defined by the asserted patents in the complaint and by any infringement contentions that follow.

(Source: case docket entry referenced in the query context.)

---

Which patents and claims are asserted in Boehringer Ingelheim v. Granules India Limited 1:25-cv-00663?

Short answer: The asserted patent set and specific asserted claims define the litigation risk, but they are not included in the information available in the docket reference provided in the prompt. Without the complaint’s exhibits or the asserted-patent list, the specific patent numbers, claim numbers, and theory (literal infringement vs. equivalents vs. method-of-use) cannot be stated accurately.

Why this matters for business analysis

• Hatch-Waxman suits can target:
  • Composition/formulation patents (salt/polymorph, dosage form)
  • Method-of-use patents (therapeutic use, patient selection, dosing)
  • Manufacturing/process patents (especially if the generic uses different crystallization steps)
• The patent category changes:
  • claim construction likelihood,
  • design-around routes,
  • the impact of “generic manufacture is different” defenses,
  • and settlement leverage.

(Source limitation: only the case identifier is provided in the prompt; asserted-patent details are not present.)

---

What is the litigation timeline for Boehringer Ingelheim v. Granules India 1:25-cv-00663?

Short answer: The case is in early stages in 2025 and the timetable is driven by initial service, the Rule 12/answer cycle, then early claim construction scheduling and typical Hatch-Waxman case management.

A business-relevant Hatch-Waxman timeline template commonly applies:

• Complaint filed and served (defines asserted patents)
• Answer/Rule 12 motions (may seek dismissal, enforceability/invalidity framing, venue/joinder issues)
• Early case conference and scheduling order
• Claim construction briefing/hearing
• Infringement contentions and invalidity contentions (often later but paced to claim construction)
• Expert discovery and dispositive motions
• Trial or settlement (many Hatch-Waxman cases resolve before full trial)

Current-case risk lens

• Early-stage cases tend to crystallize leverage around:
  • claim meaning,
  • whether Granules can design around the asserted claim elements,
  • and whether invalidity arguments look strong enough to defeat injunction risk.

(Source limitation: prompt provides only case number.)

---

Is Boehringer Ingelheim v. Granules India a Paragraph IV ANDA patent litigation?

Short answer: The action appears consistent with Hatch-Waxman ANDA-style patent litigation because it is styled as a patent infringement case between a branded innovator and a generic supplier, docketed under a Hatch-Waxman framework in federal court. The specific Paragraph IV notice and patent numbers cannot be confirmed from the prompt’s limited data.

How to interpret the “generic entry risk” angle

• If the suit tracks an ANDA with Paragraph IV:
  • the Orange Book patent list defines the exclusivity landscape,
  • and the FDA approval timing is affected by the statutory litigation stay mechanics.

Impact on launch

• Even early in the case, the branded plaintiff’s asserted patents determine whether:
  • a 30-month stay is triggered,
  • the generic can obtain tentative approval but delay commercial entry,
  • and where settlement pressure concentrates.

(Source limitation: prompt does not provide the ANDA or Paragraph IV notice details.)

---

What defenses and counterclaims are likely in Granules’ position?

Short answer: In Hatch-Waxman generic infringement suits, the usual defense set includes non-infringement and invalidity, with inequitable conduct and failure to state a claim less common as standalone early dispositive motions.

Typical invalidity theories that affect settlement value

• Anticipation/Obviousness based on prior art
• Indefiniteness (claim clarity)
• Enablement/Written description (for some technical patents)
• Noninfringement based on generic formulation/process differences or claim element absence
• Lack of enforceability arguments when tied to prosecution history or patent quality

Settlement leverage analysis (what changes when case details are known)

• Strength shifts sharply depending on:
  • whether asserted claims are composition/formulation vs method-of-use,
  • how “close” the generic product is to claim parameters (e.g., specific polymorph/salt),
  • and whether claim construction is likely to narrow key terms.

(Source limitation: prompt does not include Granules’ answer or responsive filings.)

---

How strong is Boehringer Ingelheim’s patent estate in this case?

Short answer: Strength cannot be quantified from the case identifier alone because the analysis depends on:

• which patents were asserted,
• claim breadth,
• prosecution history (which affects claim interpretation),
• and known litigation outcomes for the same patent family.

What to look for once asserted patents are identified

• Whether asserted patents are early-expiring vs. late-expiring
• Whether patents have survived prior validity challenges
• Whether there are related family members in the same jurisdiction
• Whether the claimed subject matter is chemistry-specific (often narrower) or method-of-use (often more contestable on medical practice and standard-of-care arguments)

(Source limitation: asserted patent list not provided.)

---

What generic entry risks exist for Granules if Boehringer wins?

Short answer: If BIPI obtains an infringement finding on at least one asserted patent claim and the court awards injunctive relief, Granules’ U.S. marketing of its proposed generic would be enjoined for the covered product scope tied to that patent. If BIPI’s asserted claims are broad and centered on composition/formulation, the practical exit barrier is higher.

Commercial consequence channels

• Injunction risk that delays launch and blocks design-around unless claims can be avoided
• Settlement pressure before claim construction if infringement appears likely
• Residual risk from non-adjudicated patents if additional Orange Book patents remain asserted

(Source limitation: no asserted-patent details or product target provided in prompt.)

---

What settlement posture is typical for Hatch-Waxman suits like this?

Short answer: Hatch-Waxman suits filed by brand companies against generic manufacturers often end in:

• a covenant-not-to-sue on specific product versions,
• licensing for certain launch dates or product configurations,
• or dismissal with a negotiated entry carve-out.

Settlement terms that drive economics

• timing of generic launch (sometimes in phases by dose strength)
• design-around formulation limits (e.g., polymorph selection)
• supply agreements and sublicensing
• dismissal scope tied to specific patents/claims

(Source limitation: prompt does not include any settlement agreement or motion to dismiss.)

---

What is the FDA regulatory status tied to this litigation?

Short answer: The prompt does not specify the FDA application number, reference listed drug (RLD), or Orange Book entries at issue. Those details are necessary to determine:

• ANDA status (pending vs approved),
• tentative approval date,
• 30-month stay status,
• and whether any amendments have been filed after the Paragraph IV notice.

(Source limitation: no FDA identifiers provided.)

---

Which companies are involved and what roles do they play in 1:25-cv-00663?

Short answer: The named parties are:

• Plaintiff: Boehringer Ingelheim Pharmaceuticals Inc.
• Defendant: Granules India Limited

Business interpretation of roles

• The defendant is the generic developer/manufacturer entity implicated in the infringement theory.
• Whether additional parties (e.g., U.S. ANDA holder, distributor, or other Granules affiliates) are involved depends on the complaint caption and service list, which are not provided in the prompt.

(Source limitation: only the caption and case number are available.)

---

What does the case imply for investors or licensors assessing risk?

Short answer: The presence of a 2025 S.D.N.Y. infringement action means brand counsel is actively enforcing Orange Book-related rights against a Granules pathway. For deal-making or licensing:

• diligence should focus on whether asserted patents are likely to be narrowed by claim construction, and whether they overlap with other established patent-family litigation.
• For generics and partners evaluating supply, the near-term risk is launch timing and injunction probability tied to the asserted claims.

(Source limitation: no asserted-patent details in prompt.)

---

Key Takeaways

• Boehringer Ingelheim Pharmaceuticals Inc. filed a patent infringement case against Granules India Limited in S.D.N.Y. under docket 1:25-cv-00663.
• The dispute is consistent with Hatch-Waxman Orange Book-driven infringement litigation, but the prompt does not provide the asserted patent list, RLD/ANDA identity, or Paragraph IV notice details needed for claim-level analysis.
• Early-stage cases typically turn on claim construction and the infringement/invalidity contentions that follow.
• Launch and commercial exposure hinge on whether BIPI’s asserted claims survive validity challenges and whether an injunction is likely.

---

FAQs

1. What is the court and jurisdiction for Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited 1:25-cv-00663?
   Southern District of New York, docket 1:25-cv-00663.

2. Is Boehringer Ingelheim seeking an injunction in 1:25-cv-00663?
   The prompt does not provide the requested relief in the complaint.

3. Which FDA application number is tied to 1:25-cv-00663?
   Not provided in the prompt.

4. Can Granules design around asserted claims in Hatch-Waxman cases like this?
   Design-around is possible in principle, but feasibility depends on the asserted claim elements and generic product/formulation/process specifics, which are not provided.

5. Does the lawsuit indicate a potential 30-month ANDA stay?
   The prompt does not provide the Paragraph IV notice content required to confirm a statutory stay.

---

References (APA)

1. U.S. District Court, Southern District of New York. Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited, No. 1:25-cv-00663 (filed 2025).